Dapagliflozin Reduces Systemic NLRP-3, IL-1 and PCSK9 Levels in Preclinical Models of ShortTerm Doxorubicin Cardiotoxicity: New Evidences of SGLT2i Use in Cardioncology-MedSci.cn

Dapagliflozin Reduces Systemic NLRP-3, IL-1 and PCSK9 Levels in Preclinical Models of ShortTerm Doxorubicin Cardiotoxicity: New Evidences of SGLT2i Use in Cardioncology

Maurea, N; Canale, ML; Bisceglia, I; Palma, G; Luciano, A; Bruzzese, F; Iovine, M; Merola, A; Paccone, A; Gabrielli, D

CIRCULATION, 2023; 148 ():

科室
- - 订阅+
  - 更多科室
工具
服务